Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2015-08-26 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Admedus HSV-2 Phase II Study Interim Update 3 pages 316.8KB
Capital/Financing Update Classification · 90% confidence The document is an ASX release announcing the continuation of a clinical study after a positive interim independent safety review. It includes details about the study progress, safety review committee findings, and an increase in the company's stake in a related vaccine company. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about clinical trial progress and investment updates, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) due to the announcement of increased stake in Admedus Vaccines and study progress updates relevant to investors.
2015-08-26 English
Annual Report to shareholders and Appendix 4E 67 pages 353.6KB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Preliminary Final Report' for the financial year ended 30 June 2015, issued by Admedus Limited. It contains detailed financial results including revenues, losses, dividends, net tangible asset backing, and a comprehensive results commentary. It also includes sections such as Directors' Report, Independence Declaration, Consolidated Financial Statements, Directors' Declaration, and Independent Auditor's Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis for the full fiscal year. The presence of audited financial statements and detailed management discussion confirms this is a full annual report. The document is not merely an announcement or a certification but the full report itself. Therefore, the appropriate classification is Annual Report (10-K). FY 2015
2015-08-26 English
Appendix 3B 15 pages 1.2MB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B – Exercise of Options' and is addressed to the Australian Stock Exchange (ASX). It details the allotment of shares to executives upon exercise of options and includes extensive information about the securities issued, issue prices, and compliance with ASX listing rules. Appendix 3B is a standard form used in Australia for announcements of new issues of securities, including share allotments and option exercises. The content is regulatory in nature, focused on notifying the market of a capital change event rather than providing financial results or management commentary. It is not an annual report, earnings release, or management discussion. The document is a formal announcement of a share issue and option exercise, fitting the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is the announcement itself, not a brief notice or report publication announcement.
2015-08-16 English
Appendix 3B - Options exercised 16 pages 1.2MB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Stock Exchange (ASX) announcement used to notify the market of the allotment of new shares upon the exercise of options. It details the number of shares issued, exercise price, and compliance with ASX listing rules. The document is a formal announcement of a share issue event, not a financial report or detailed analysis. It does not contain financial statements or management discussion but focuses on capital changes related to share allotment. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing fallback. Confidence is high due to the clear identification of the form and content.
2015-08-02 English
Appendix 4C - quarterly 7 pages 339.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C - Quarterly Report' and is addressed as an announcement to the Australian Stock Exchange. It contains detailed financial data for the quarter and full year ended 30 June 2015, including revenue, cash flows, and operational highlights. The presence of consolidated cash flow statements and detailed quarterly financial results indicates this is a comprehensive interim financial report rather than a brief announcement or certification. The document length (over 10,000 characters) and detailed financial data confirm it is not merely a report publication announcement or regulatory filing. The quarterly nature and detailed financial statements align with the definition of an Interim / Quarterly Report (IR). FY 2015
2015-07-29 English
Appendix 3B - Issue of Options 14 pages 892.8KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard announcement for the issue of new securities (in this case, unlisted options) by a company listed on the Australian Stock Exchange (ASX). It details the allotment of 13,500,000 unlisted options to employees under an Employee Share Option Plan, including terms, issue price, and compliance with ASX listing rules. The document is a formal announcement of a capital raising event (issue of new securities) rather than a full financial report or other types of filings. It does not contain financial statements or management discussion but focuses on the issuance and quotation of new securities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued, supporting a high confidence in classification.
2015-07-21 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.